23348
L-Allylglycine
Cayman Chemical
DESCRIPTION
A GAD inhibitor; reduces GAD activity by 60% when administered at a dose of 39.8 μmol/g per hour ex vivo in mouse brain preparations; i.p. administration (1.2 mmol/kg) induces convulsions and decreases GABA concentration throughout the cerebellum, pons, medulla, striatum, cortex, and hippocampus in mice; chronic administration (3.2 μg/0.5 μl per hour for 13 days) increases locomotor activity in an open field test and impairs attention in the 5-choice serial reaction time task (5CSRTT); inhibits GAD in vitro only when used at high concentrations (1-80 mM)
DETAILS
- Inchi: InChI=1S/C5H9NO2/c1-2-3-4(6)5(7)8/h2,4H,1,3,6H2,(H,7,8)/t4-/m0/s1
- Purity: ≥95%
- Raptas: Product Type|Biochemicals|Small Molecule Inhibitors||Research Area|Neuroscience|Seizure Disorders
- Smiles: OC([C@@H](N)CC=C)=O
- Inchikey: WNNNWFKQCKFSDK-BYPYZUCNSA-N
- Cas Number: 16338-48-0
- Formulation: A crystalline solid
- Storage Temp: -20
- Shipping Temp: -20
- Formula Markup: C5H9NO2
- Formula Weight: 115.1
- Shelf Life Days: 1460